Paul Carney

Prof. Paul Carney

Division of Pediatric Neurology, Department of Child Health, University of Missouri at Columbia, 404 Keene Street, Columbia, MO 65201, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 October 2019 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
BGBin Gu
Bin Gu
MZManhua Zhu
Manhua Zhu
MGMadison R. Glass
Madison R. Glass
MRMarie Rougié
Marie Rougié
VNViktoriya D. Nikolova
Viktoriya D. Nikolova
BPBenjamin D. Philpot
Benjamin D. Philpot
Angelman syndrome (AS) is a neurodevelopmental disorder characterized by intellectual disability, lack of speech, ataxia, EEG abnormalities, and epilepsy. Seizures in AS individuals are common, debilitating, and often drug-resistant. Therefore, there is an unmet need for better treatment options. Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, has antiseizure activity and behavioral benefits in preclinical and clinical studies for some disorders associated with epilepsy, suggesting that the same could be true for AS. Here we show that acute CBD (100 mg/kg) attenuated hyperthermia- and acoustically-induced seizures in a mouse model of AS. However, neither acute CBD nor a two-weeklong course of CBD administered immediately after a kindling protocol could halt the pro-epileptogenic plasticity observed in AS model mice. CBD had a dose-dependent sedative effect, but did not have an impact on motor performance. CBD abrogated the enhanced intracortical local field potential power, including delta and theta rhythms observed in AS model mice, indicating that CBD administration could also help normalize the EEG deficits observed in individuals with AS. Our results provide critical preclinical evidence supporting CBD treatment of seizures and alleviation of EEG abnormalities in AS, and will thus help guide the rational development of CBD as an AS treatment.

10 September 2022 in Children
Verified
Journal Article
Open access
PDF file
KNKyra Newmaster
Kyra Newmaster
ZZZahra Zhu
Zahra Zhu
EBElizabeth Bolt
Elizabeth Bolt
RCRyan J. Chang
Ryan J. Chang
CDChristopher Day
Christopher Day
SNSunil Naik
Sunil Naik
Ketogenic diets (KDs) are highly effective in the treatment of epilepsy. However, numerous complications have been reported. During the initiation phase of the diet, common side effects include vomiting, hypoglycemia, metabolic acidosis and refusal of the diet. While on the diet, the side effects involve the following systems: gastrointestinal, hepatic, cardiovascular, renal, dermatological, hematologic and bone. Many of the common side effects can be tackled easily with careful monitoring including blood counts, liver enzymes, renal function tests, urinalysis, vitamin levels, mineral levels, lipid profiles, and serum carnitine levels. Some rare and serious side effects reported in the literature include pancreatitis, protein-losing enteropathy, prolonged QT interval, cardiomyopathy and changes in the basal ganglia. These serious complications may need more advanced work-up and immediate cessation of the diet. With appropriate monitoring and close follow-up to minimize adverse effects, KDs can be effective for patients with intractable epilepsy.

1 September 2017 in Pediatric Neurology
Verified
Journal Article
Closed access
XLXinyue Liu
Xinyue Liu
Paul CarneyPaul Carney
Paul Carney
RBRegina Bussing
Regina Bussing
RSRichard Segal
Richard Segal
Linda B CottlerLinda B Cottler
Linda B Cottler
AWAlmut G. Winterstein
Almut G. Winterstein

22 September 2022 in Children
Verified
Journal Article
Open access
PDF file
EREdith Riggs
Edith Riggs
ZSZaynab Shakkour
Zaynab Shakkour
CAChristopher Logan Anderson
Christopher Logan Anderson
Paul CarneyPaul Carney
Paul Carney
Synaptic dysregulations often result in damaging effects on the central nervous system, resulting in a wide range of brain and neurodevelopment disorders that are caused by mutations disrupting synaptic proteins. SYT1, an identified synaptotagmin protein, plays an essential role in mediating the release of calcium-triggered neurotransmitters (NT) involved in regular synaptic vesicle exocytosis. Considering the significant role of SYT1 in the physiology of synaptic neurotransmission, dysfunction and degeneration of this protein can result in a severe neurological impairment. Genetic variants lead to a newly discovered rare disorder, known as SYT1-associated neurodevelopment disorder. In this review, we will discuss in depth the function of SYT1 in synapse and the underlying molecular mechanisms. We will highlight the genetic basis of SYT1-associated neurodevelopmental disorder along with known phenotypes, with possible interventions and direction of research.

1 October 2022 in Children
Verified
Journal Article
Open access
PDF file
ZZZahra Zhu
Zahra Zhu
EBElizabeth Bolt
Elizabeth Bolt
KNKyra Newmaster
Kyra Newmaster
WOWendy Osei-Bonsu
Wendy Osei-Bonsu
SCStacey Cohen
Stacey Cohen
SNSunil Naik
Sunil Naik
Background: Pathogenic variants in SCN1B, the gene encoding voltage-gated sodium channel b1/b1B subunits are associated with a spectrum of epileptic disorders. This study describes a child with early myoclonic encephalopathy and a compound heterozygous variant in the SCN1B gene (p.Arg85Cys and c.3G>C/p.Met1), along with the child’s clinical response to anti-seizure medications (ASMs) and the ketogenic diet. We reviewed the current clinical literature pertinent to SCN1B-related epilepsy. Methods: We described the evaluation and management of a patient with SCN1B-related developmental and epileptic encephalopathy (DEE). We used the Medline and Pubmed databases to review the various neurological manifestations associated with SCN1B genetic variants, and summarize the functional studies performed on SCN1B variants. Results: We identified 20 families and six individuals (including the index case described herein) reported to have SCN1B-related epilepsy. Individuals with monoallelic pathogenic variants in SCN1B often present with genetic epilepsy with febrile seizures plus (GEFS+), while those with biallelic pathogenic variants may present with developmental and epileptic encephalopathy (DEE). Individuals with DEE present with seizures of various semiologies (commonly myoclonic seizures) and status epilepticus at early infancy and are treated with various antiseizure medications. In our index case, adjunctive fenfluramine was started at 8 months of age at 0.2 mg/kg/day with gradual incremental increases to the final dose of 0.7 mg/kg/day over 5 weeks. Fenfluramine was effective in the treatment of seizures, resulting in a 50% reduction in myoclonic seizures, status epilepticus, and generalized tonic-clonic seizures, as well as a 70–90% reduction in focal seizures, with no significant adverse effects. Following the initiation of fenfluramine at eight months of age, there was also a 50% reduction in the rate of hospitalizations. Conclusions: SCN1B pathogenic variants cause epilepsy and neurodevelopmental impairment with variable expressivity and incomplete penetrance. The severity of disease is associated with the zygosity of the pathogenic variants. Biallelic variants in SCN1B can result in early myoclonic encephalopathy, and adjunctive treatment with fenfluramine may be an effective treatment for SCN1B-related DEE. Further research on the efficacy and safety of using newer ASMs, such as fenfluramine in patients under the age of 2 years is needed.

1 February 2017 in Epilepsy Research
Verified
Journal Article
Closed access
GNGowri Natarajan
Gowri Natarajan
JLJeffrey A. Leibowitz
Jeffrey A. Leibowitz
JZJunli Zhou
Junli Zhou
YZYang Zhao
Yang Zhao
JMJessica A. McElroy
Jessica A. McElroy
Paul CarneyPaul Carney
Paul Carney